600276 恒瑞医药
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入13,600,73421.78%22,819,78521,275,27125,905,52627,734,599
减:营业总成本9,756,00011.77%18,214,15317,747,08421,792,96921,282,046
    其中:营业成本1,873,3045.87%3,525,2483,486,6393,741,7993,348,690
               财务费用(382,222)56.76%(478,390)(470,867)(337,956)(181,744)
               资产减值损失15,816--(107,217)(146,684)(13,861)(7,278)
公允价值变动收益7,542-127.30%(58,257)76,50336,23316,497
投资收益(16,140)68.86%(49,157)387,365213,434341,425
    其中:对联营企业和合营企业的投资收益(34,377)-17.77%(72,696)(62,996)(6,940)--
营业利润3,984,77655.04%4,909,9054,111,9604,664,8167,007,072
利润总额3,751,60049.32%4,667,1103,968,4924,466,3096,895,480
减:所得税费用323,46845.68%389,289153,351(17,718)586,587
净利润3,428,13249.67%4,277,8213,815,1424,484,0276,308,893
减:非控股权益(3,616)-79.75%(24,615)(91,233)(46,191)(19,490)
股东净利润3,431,74848.67%4,302,4363,906,3754,530,2186,328,383

市场价值指针
每股收益 (元) *0.54050.00%0.6800.6100.7100.990
每股派息 (元) *----0.2000.1600.1600.200
每股净资产 (元) *6.6829.68%6.3445.9295.4735.721
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容